Nasdaq

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

In the first ever disclosure for the subcutaneous formulation of Opdivo, the CheckMate -67T Phase 3 trial demonstrates activity in advanced or metastatic clear cell renal cell carcinoma Company plans ...
Nasdaq

Bristol Myers: CheckMate -914 Part A Trial With Opdivo Plus Yervoy Fails To Meet Primary Goal

(RTTNews) - Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) Friday announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab), as ...
Seeking Alpha

Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for ...

BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- Halozyme ...
News 6 WKMG

Checkmate or knockout? 3 things to know about chessboxing

There are several sports that combine multiple two disciplines, such as biathlon (cross-country skiing), nordic combined (ski jumping, cross-country skiing) and the decathlon or heptathlon in track ...
ascopubs.org

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study ...